NeuroSense Therapeutics Ltd.
No SEC Form 4 filings for $NRSN in the last 30 days.
See all $NRSN insider activity →NeuroSense Therapeutics Ltd. (NRSN) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 NeuroSense Provides Business Update and Progress for the First Half of 2026 CAMBRIDGE, Mass., September 25, 2026 -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) (“NeuroSense” or the “Company”), a late-stage clinical biotechnology company focused on developing disease-
NeuroSense Therapeutics (NRSN) announced a redesigned development strategy for PrimeC in ALS, aiming to accelerate regulatory approval and reduce costs. The strategy includes AI-enabled formulation analysis, a comparative study against edaravone, and an optimized Phase 3 trial design. The company has received FDA clearance and is targeting a Canadian regulatory submission by December 2026. PrimeC is an investigational oral therapy combining ciprofloxacin and celecoxib.
NeuroSense Therapeutics (NASDAQ: NRSN) said the FDA cleared it to start the Phase 3 PARAGON study of PrimeC in ALS, targeting about 300 participants, mainly in the U.S. The company is seeking financing to fund initiation, expects to submit an NDS in Canada in Dec 2026, and plans a possible 1:4 to 1:40 reverse split to address Nasdaq bid-price issues.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning NRSN (NeuroSense Therapeutics Ltd.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent NRSN coverage spans financial news, earnings and insider activity.
Net loss widened YoY but R&D spend fell; positive Phase 2b data may support future valuation uplift.
The new strategy could accelerate regulatory filing and reduce costs, potentially improving valuation.
Near-term trading hinges on whether the company can secure PARAGON funding and avoid Nasdaq delisting risk.
Regulatory process alignment reduces timeline uncertainty for PrimeC’s Canadian submission, supporting a near-term sentiment bid while leaving approval risk unchanged.
Positive Phase 2b efficacy/biomarker readout increases probability of successful confirmatory Phase 3 and supports risk-on positioning in NRSN.
AlphAI scores every news story that mentions NRSN with an AI model for sentiment and relevance, and aggregates insider trades from NeuroSense Therapeutics Ltd.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
NeuroSense Therapeutics Ltd. (NRSN) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 NeuroSense Provides Business Update and Progress for the First Half of 2026 CAMBRIDGE, Mass., September 25, 2026 -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) (“NeuroSense” or the “Company”), a late-stage clinical biotechnology company focused on developing disease-
2 min readNeuroSense Therapeutics (NRSN) announced a redesigned development strategy for PrimeC in ALS, aiming to accelerate regulatory approval and reduce costs. The strategy includes AI-enabled formulation analysis, a comparative study against edaravone, and an optimized Phase 3 trial design. The company has received FDA clearance and is targeting a Canadian regulatory submission by December 2026. PrimeC is an investigational oral therapy combining ciprofloxacin and celecoxib.
2 min readNeuroSense Therapeutics (NASDAQ: NRSN) said the FDA cleared it to start the Phase 3 PARAGON study of PrimeC in ALS, targeting about 300 participants, mainly in the U.S. The company is seeking financing to fund initiation, expects to submit an NDS in Canada in Dec 2026, and plans a possible 1:4 to 1:40 reverse split to address Nasdaq bid-price issues.
3 min readNeuroSense Therapeutics (NASDAQ: NRSN) says it has completed the Pre-NDS process with Health Canada for its ALS drug PrimeC and is targeting an NDS filing in early December 2026. Health Canada aligned on submission content and structure and raised no concerns. The NDS would be supported by Phase 2b PARADIGM results, including HR 0.35 (p=0.0037) median survival benefit.
4 min readNeuroSense Therapeutics (NASDAQ: NRSN) said its Phase 2b PARADIGM trial of PrimeC in ALS met the primary endpoint: at Day 180, TDP-43 fell vs placebo (p=0.0421), with differences sustained at Day 540 (p<0.001). The company also reported slower ALSFRS-R decline and a median survival benefit (HR 0.35, p=0.004), plus no new safety signals, and said FDA clearance was obtained for Phase 3.
4 min readBen-Noon Alon (Chief Executive Officer) purchased 250,000 shares of NeuroSense Therapeutics Ltd. (NRSN) at $0.80 ($0.20M total) on 2026-06-16.
1 min readEisenberg Or (Chief Financial Officer) purchased 250,000 shares of NeuroSense Therapeutics Ltd. (NRSN) at $0.80 ($0.20M total) on 2026-06-16.
2 min readNeuroSense Therapeutics has received two notifications from Nasdaq indicating non-compliance with minimum bid price ($1.00 per share) and market value of listed securities ($35 million) requirements. These notifications do not immediately affect the trading of the company's shares. NeuroSense has 180 calendar days, until September 29, 2026, to regain compliance and is actively evaluating options to achieve this while focusing on long-term shareholder value.
3 min readNeuroSense Therapeutics Ltd. CTO Niva Russek-Blum has filed an initial ownership report detailing her equity holdings in the company. The report includes 36,000 fully vested options at an exercise price of $2.18, significant blocks of ordinary shares totaling over 250,000, and 10,000 restricted share units with varying vesting schedules. These disclosures provide transparency regarding the executive's stake in NeuroSense.
2 min readNeuroSense Therapeutics Ltd. (NRSN) Chief Technology Officer Niva Russek-Blum was granted 200,000 restricted Ordinary Shares as compensation. These shares, with a stated price of $0.00 per share, will vest in equal quarterly installments over a two-year period beginning March 26, 2026, contingent on her continued service. This grant increases her direct holdings to 467,953 Ordinary Shares and is subject to Section 102 of the Israeli Tax Ordinance for certain tax benefits.
2 min read
